Current Investigator-led Research

Biomarkers of COVID-19

Principal Investigator: Dr Yin Lim

Associate Investigators: A/Prof Prahlad Ho, Dr Kay Weng Choy, Dr Julie Wang, Mr Niki Lee, Dr Yvonne Hersusianto

Status: Active

Retrospective evaluation of COVID-19 patients

Principal Investigator: Dr Yin Lim

Associate Investigators: A/Prof Prahlad Ho, Dr Kay Weng Choy, Dr Julie Wang, Dr Rowena Brook

Status: Active

Global Coagulation Assays in Patients with High-Risk Cardiovascular Risk Factors

Principal investigator: Dr Yin Lim

Associate investigators: A/Prof Prahlad Ho, Dr David Barit, Dr Suresh Varadarajan, Dr Carol Chong

Status: Active – currently recruiting

Prospective Serial Evaluation of New Biomarkers of Thrombosis in Patients with Newly Diagnosed Venous Thromboembolism

Principal Investigator: Dr Julie Wang

Associate investigators: Dr Yin Lim, A/Prof Prahlad Ho

Status: Active – currently recruiting

Evaluation of New Biomarkers of Thrombosis in a Normal Population As Well As Anticoagulated and Hypercoagulable States

Principal Investigator: A/Prof Prahlad Ho, Dr Yin Lim

Associate investigators: Dr Julie Wang

Status: Active – currently Recruiting

Venous Thromboembolism Retrospective Review

Principal Investigator: Dr Yin Lim

Co-Investigators: A/Prof Prahlad Ho, Dr Brandon Lui

Status: Active

Global Coagulation Assays in Cancer Patients

Principal Investigators: Dr Yin Lim, A/Prof Prahlad Ho

Status: To commence

 

Publications & Presentations

2022

  • Enjeti A, Agarwal R, Blombery P, Chee L, Chua CC, Grigg A, Hamad A, Iland H, Lane S, Perkins A, Singhal D, Tate C, Tiong IS, Ross DM. Panel-based gene testing in myelodysplastic/myeloproliferative neoplasms overlap syndromes: ALLG consensus statement. 2022 (accepted with minor revision).
  • Doig C, Cooke R, Chua C, Leung T. Acute respiratory distress syndrome precipitated by growth-colony stimulating factor in undiagnosed Pneumocystis jiroveci pneumonia. BMJ Case Reports Feb 2022, 15 (2) e242316; DOI: 10.1136/bcr-2021-242316.
  • Wang, J., Lim, H. Y., Nandurkar, H. & Ho, P. Age, sex and racial differences in fibrin formation and fibrinolysis within the healthy population. Blood Coagul Fibrin 33, 141–144 (2022).
  • Lim HY, Donnan G, Nandurkar H, Ho P. Global coagulation assays in hypercoagulable states. J Thromb Thrombolysis (2022). https://doi.org/10.1007/s11239-021-02621-1

 

2021

  • Lim HY, Lui B, Tacey M, Kwok A, Varadarajan S, Donnan G, Nandurkar H, Ho P. Global coagulation assays in patients with diabetes mellitus. Res Pract Thromb HaemOct 2021; 5(7): e12611.
  • O’Keefe D, Lim HY, Hui L, Ho P. Risk stratification for pregnancy-associated venous thromboembolism: Potential role for global coagulation assays. Obs Med https:://doi.org/10.1177/1753495X211025397
  • Wang J, Lim HY, Ho P. Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. 2021; 2(1):64-78
  • Lim, H.Y., Choy, K.W., Wang, J., Nandurkar, H. and Ho, P. (2021), Global coagulation assays – Proposed reference intervals for healthy controls. Int J Lab Hematol.https://doi.org/10.1111/ijlh.13746
  • Brook R, Lim HY, Ho P, Choy KW. Risk factors and early prediction of clinical deterioration and mortality in adult COVID‐19 inpatients: an Australian tertiary hospital experience.Internal Medicine Journal 2021 Nov 22.
  • Lim HY, Lui B, Tacey M, Selan C, Donnan G, Burrell L, Nandurkar H, Ho P. Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system? J Thromb Thrombolysis2021;52:610-9.
  • Bergin et al.​ Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplant. 2021 Oct; 56(10): 2533-2543. doi: 10.1038/s41409-021-01308-8. Epub 2021 May 19.

Presentations

Blood Annual Scientific Meeting:

  • Overall Haemostatic Potential identifies greater severity of COVID-19 infection. Lee NCK, Brook R, Lim HY, Ho P, Wang J.
  • Overall Haemostatic Potential assay detects increased fibrin generation and reduced fibrinolysis potential in anticoagulated patients following venous thromboembolism. Wang J, Ho P.
  • Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. Tedjaseputra A, Kuzich J, Anton, Thiagarajah N, Teh TC, McClelland J, Rahman M, Brook R, Chua CC, Ong DM, Tan SY, Filshie R, Fong CY, Pasquale F, Bajel A, Shortt J, Wei AH.

ISTH Annual Scientific Meeting:

  • Overall Haemostatic Potential assay can detect hypercoagulability and hypofibrinolysis in anticoagulated patients following venous thromboembolism. Wang J, Ho P

2020

  • Wang J, Tacey M, Ho P. Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world? Journal of Thrombosis and Thrombolysis. 2020;49(4):562-71
  • Lim HY, Brook R, Leemaqz SY, Torkamani N, Grossmann M Zajac JD, Nandurkar H, Ho P, Cheung A. Global coagulation assays in transgender women on oral and transdermal estradiol therapy. J Clin Endo Metab 2020 (accepted for publication 8 May 2020)
  • Lim HY, Lambros P, Krishnamoorthi B, Chellaram V, Ho P. Outpatient management of deep vein thrombosis using direct oral anticoagulants is safe and efficient. J Pharm Pract Res (accepted for publication 4 March 2020)
  • Lui B, Ho P, Lim HY. Superficial venous thrombosis: is it as benign as we think? J Thromb Thrombolysis 2020 (accepted for publication 13 February 2020)
  • Brook R, Aswapanyawongse N, Tacey M, Kitipornchai T, Ho P, Lim HY. Real-world direct oral anticoagulants experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk. Intern Med J2020;50:1359-66.

Presentations

ISTH Annual Scientific Meeting:

  • Evaluation of thrombin and fibrin generation in venous thromboembolism (VTE) patients receiving anticoagulation.Wang J, Lim H-Y, Brook, R, Aswapanyawongse O, Ho P.

 

2019

  • Wang J, McBride L, Ho P, Langsford D. Dabigatran toxicity in acute kidney injury: hemodialysis and idarucizumab required. Kidney Int Rep2019; 4: 500-504.
  • Lim HY, Brook R, Krishnamoorthi B, Tacey M, Leung T, Donnan G, Nandurkar H, Ho P. Global coagulation assays in patients with multiple myeloma and monoclonal gammopathy of unknown significance. Thromb Res2019;183:45-48.
  • Lim HY, O’Malley Cindy, Donnan G, Nandurkar H, Ho P.  A review of global coagulation assays – Is there a role in thrombosis risk prediction? Thromb Res2019;179:45-55.
  • Lim HY, Leung P, Manitta V, Nandurkar H, Ho P. A comparison of global coagulation assays between normal controls and patients with thrombocytopenia. Int J Lab Hematol2019;41:184-191.
  • Lim HY, Ho P, Bayat I, Hong F. Thrombophlebitis post varicose vein surgery: To treat or not to treat? EC Clin Med Case Reports2019;2:38-42.

 

2018

  • Lim HY, Ng C, Tacey M, Donnan G, Nandurkar H, Ho P. An evaluation of global coagulation assays in myeloproliferative neoplasm. Blood Coagul Fibrinolysis2018; 28:300-306.
  • Lim HY, Nandurkar H, Ho P. Direct oral anticoagulants and the paradigm shift in the management of venous thromboembolism. Semin Thromb Haemost2018;44:261-266.

Presentations

ASH Annual Scientific Meeting:

  • Post-anticoagulation cessation D-dimer testing and VTE recurrence in real-world Australian audit. Wang J, Brook R, Hong L, Slocombe A, Ho P.

HAA Annual Scientific Meeting:

  • Post-anticoagulation cessation D-dimer testing reduces VTE recurrence in real-world Australian audit. Wang J, Brook R, Hong L, Slocombe A, Ho P.
  • Abnormal D-dimer post-cessation of anticoagulation predicts recurrent thrombosis in non-surgically provoked VTE and distal DVT. Wang J, Brook R, Hong L, Slocombe A, Ho P.
  • Combined haemodialysis and multiple idarucizumab doses are required for Dabigatran reversal in severe acute kidney injury and bleeding. Wang J, McBride L, Ho P, Langsford D.